Squamous cell carcinoma antigen in hepatocellular carcinoma: Ready for the prime time?

Montagnana, Martina; Danese, Elisa; Lippi, Giuseppe

doi:10.1016/j.cca.2015.03.031

Cited by 12 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 Therefore, implementation of more sensitive and specific tumour markers for HCC detection is the focus of many researches in order to improve sensitivity and objectify diagnosis. [5][6][7]9 Besides AFP, some of the potential serum tumour markers for HCC detection include protein induced by vitamin K absence or antagonist-II (PIVKAII), 7,10,11 Glypican-3 (GP3), 7,10,12,13 squamous cell carcinoma antigen 1 (SCCA1), [14][15][16] while data on the performance of Cystatin B and hepatocyte growth factor (HGF) are still unclear. 17,18 PIVKAII is the second most commonly investigated marker for HCC besides AFP.…”

Section: Introductionmentioning

confidence: 99%

“…SCCA is a member of serine protease inhibitor family, and recent studies have shown that SCCA consists of two homologous proteins SCCA1 and SCCA2. 16 Although SCCA1 is found to be elevated in patients with HCC, its usefulness in diagnosing HCC is still doubtful. [14][15][16] Cystatins are endogenous inhibitors of lysosomal cysteine proteinases (cathepsin L, H, and S).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic specificity and sensitivity of PIVKAII, GP3, CSTB, SCCA1 and HGF for the diagnosis of hepatocellular carcinoma in patients with alcoholic liver cirrhosis

et al. 2017

View full text Add to dashboard Cite

Introduction Despite some new treatment possibilities, the improvement in survival rate for hepatocellular carcinoma (HCC) patients is still poor due to late diagnosis. The aim of this study was to investigate the diagnostic sensitivity and specificity of protein induced by vitamin K absence or antagonist-II (PIVKAII), Glypican-3 (GP3), Cystatin B (CSTB), squamous cell carcinoma antigen 1 (SCCA1) and hepatocyte growth factor (HGF) as potential tumour markers for HCC in patients with alcoholic liver cirrhosis (ALC) using imaging techniques (MSCT and MRI) as reference standards. Patients and methods Eighty-three participants were included: 20 healthy volunteers, 31 patients with ALC and 32 patients with HCC. Peripheral blood sampling was performed for each participant, and serum concentrations of PIVKAII, GP3, CSTB, SCCA1 and HGF were determined using commercial ELISA kits. Results Only serum concentrations of PIVKAII were significantly higher in HCC patients as compared with ALC and healthy controls (cut-off: 2.06 µg/L; AUC: 0.903), whereas individual diagnostic performance of other individual compounds was inadequate. The 'best' combination of tumour markers in our study includes all tested markers with AUC of 0.967. Conclusion While novel diagnostic tumour markers are urgently needed, the examined potential tumour markers, with the exception of PIVKAII seem to be inadequate for diagnosing HCC in ALC. Furthermore, probably the future is in finding the best optimal combination of tumour markers for diagnosing HCC based on cost-effectiveness.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Diagnostic specificity and sensitivity of PIVKAII, GP3, CSTB, SCCA1 and HGF for the diagnosis of hepatocellular carcinoma in patients with alcoholic liver cirrhosis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Squamous cell carcinoma antigen (SCCA), as a member of the serine protease inhibitors family, is often used as a tumour marker with squamous cell carcinoma 1 2 . The SCCA normally exists in basal and parabasal layers of normal squamous epithelium with a low level, but it is found to be overexpressed in epithelia of cancerous tissue 3 .…”

mentioning

confidence: 99%

A Novel Controlled Release Immunosensor based on Benzimidazole Functionalized SiO2 and Cyclodextrin Functionalized Gold

Wang

et al. 2016

Sci Rep

View full text Add to dashboard Cite

A novel controlled release system-based sandwich-type immunosensor is fabricated to detect squamous cell carcinoma antigen (SCCA). The 1-methyl-1H-benzimidazole functionalized mesoporous SiO2 (MBI-MS) is used to load methylene blue (MB). β-cyclodextrin functionalized gold (CD-Au) is introduced as the gatekeeper for encapsulating MB and capturing the adamantly functional detection antibody (ADA-Ab2). And pH stimulus serves as the trigger system to control the MB release. After the load of MB, the CD-Au blocks the pores of the MBI-MS by the host-guest interaction in the neutral condition. However, when the pH is below 7.0, CD-Au is separated from the surface of MBI-MS owing to the protonation of the aromatic amines. The encapsulated MB is released from the pores of MBI-MS and detected by square wave voltammetry. The controlled release immunosensor shows a relatively wide linear range from 0.001 to 20 ng·mL−1 with a low detection limit of 0.25 pg·mL−1. The immunosensor also shows good reproducibility and selectivity, which endows it broad application prospect in clinical research.

show abstract

“…SCCA-IgM in chronic hepatitis C [57] 52-89 50-82 AFP [58] 41-65 80-94 Osteopontin [58] 87 82 DCP [58] 23-89 95 AFP-L3 [58] 37-60 90-92 AFP: Alpha-fetoprotein; SCCA-IgM: Squamous cell carcinoma antigenimmunoglobulins M.…”

mentioning

confidence: 99%

Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C

Martini

Gallotta

Pontisso

et al. 2015

WJH

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is the main cause of chronic liver disease and cirrhosis in Western countries. Over time, the majority of cirrhotic patients develop hepatocellular carcinoma (HCC), one of the most common fatal cancers worldwide -fourth for incidence rate. A high public health priority need is the development of biomarkers to screen for liver disease progression and for early diagnosis of HCC development, particularly in the high risk population represented by HCV-positive patients with cirrhosis. Several studies have shown that serological determination of a novel biomarker, squamous cell carcinoma antigen-immunoglobulins M (SCCA-IgM), might be useful to identify patients with progressive liver disease. In the initial part of this review we summarize the main clinical studies that have investigated this new circulating biomarker on HCV-infected patients, providing evidence that in chronic hepatitis C SCCA-IgM may be used to monitor progression of liver disease, and also to assess the virological response to antiviral treatment. In the last part of this review we address other, not less important, clinical applications of this biomarker in hepatology. Core tip: A high public health priority need is the development of biomarkers to screen for liver disease progression in hepatitis C virus (HCV)-positive patients. Serological squamous cell carcinoma antigen-immunoglobulins M has shown the ability to identify patients with progressive liver disease and patients at higher risk of hepatocellular carcinoma development. In this review we summarize the main clinical studies performed using this new circulating biomarker for monitoring cirrhosis progression in HCV-positive patients and to evaluate virological response to antiviral treatment. Clinical applications of squamous cell carcinoma antigenimmunoglobulins M to monitor chronic hepatitis C Martini A, Gallotta A, Pontisso P, Fassina G. Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C. MINIREVIEWS

show abstract

Squamous cell carcinoma antigen in hepatocellular carcinoma: Ready for the prime time?

Cited by 12 publications

References 34 publications

Diagnostic specificity and sensitivity of PIVKAII, GP3, CSTB, SCCA1 and HGF for the diagnosis of hepatocellular carcinoma in patients with alcoholic liver cirrhosis

Diagnostic specificity and sensitivity of PIVKAII, GP3, CSTB, SCCA1 and HGF for the diagnosis of hepatocellular carcinoma in patients with alcoholic liver cirrhosis

A Novel Controlled Release Immunosensor based on Benzimidazole Functionalized SiO2 and Cyclodextrin Functionalized Gold

Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C

Contact Info

Product

Resources

About